This can make it harder to lose weight, even with semaglutide
For the anti-diabetic medications (ADMs), the number of patients prescribed an ADM in December 2023 remained about the same as the number in both November 2023 and October 2023
A Groundbreaking Approval In late 2024, the FDAs approval of Zepbound for the treatment of OSA marks the first time a GLP-1 receptor agonist has been cleared for use outside of weight management and diabetes treatment
Other symptoms Along with digestive changes, some people taking semaglutide report shifts in energy, sleep, or mood, especially during the first few weeks of treatment or when increasing the dose
This deserves special attention regarding fatigue because glucagon has a complex relationship with energy
David Rind, chief medical officer for the Institute for Clinical and Economic Review, which estimates the value of drugs